Description of participants who were undiagnosed and untreated at baseline with followup data within 6 months of screening, by program phase. Values are n (%) unless otherwise specified.
| Characteristics | Phase I: Education and Communication to PCP, n = 3997 | Phase II: Education, BMD Testing, and Risk Assessment, and Communication to PCP | ||
|---|---|---|---|---|
| All Eligible at Active Phase II Sites, n = 1363 | Confirmed Participants, n = 569 | Eligible Nonparticipants, n = 794 | ||
| Sociodemographics | ||||
| Age, yrs, mean ± SD | 68.5 ± 11.2 | 67.9 ± 11.2 | 65.2 ± 10.2 | 69.8 ± 11.5 |
| Sex | ||||
| Male | 905 (22.6) | 367 (26.0) | 191 (33.6) | 176 (22.2) |
| Female | 3092 (77.4) | 996 (73.1) | 378 (66.4) | 618 (77.8) |
| Fracture location a | ||||
| Hip | 423 (10.6) | 164 (12.0) | 68 (12.0) | 96 (12.1) |
| Wrist | 1470 (36.8) | 549 (40.3) | 255 (44.8) | 294 (37.0) |
| Shoulder | 716 (17.9) | 203 (14.9) | 94 (16.5) | 109 (13.7) |
| Ankle | 651 (16.3) | 213 (15.6) | 49 (8.6) | 164 (20.7) |
| Other b | 737 (18.4) | 234 (17.1) | 103 (18.1) | 131 (16.5) |
| Osteoporosis-related outcomes at 6 mos | ||||
| Had a BMD test done | 2612 (65.4) | 977 (71.7) | 541 (95.1) | 436 (54.9) |
| BMD test results (of those tested) | ||||
| High risk | – | – | 231 (42.7) | – |
| Moderate risk | – | – | 284 (52.5) | – |
| Missing | – | – | 26 (4.8) | – |
| Treatment initiation | 821 (20.5) | 359 (26.3) | 203 (35.7) | 156 (19.6) |
| Treatment initiation among those who had a BMD test result indicating: | ||||
| High risk | – | – | 132 (57.1) | – |
| Moderate risk | – | – | 65 (22.9) | – |